Compare Enovix Corporation (ENVX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs GeneDx Holdings Corp — how do they compare? Enovix Corporation trades at $4.85 (market cap $1.11B), while GeneDx Holdings Corp trades at $65.6 (market cap $1.96B). The key difference: GeneDx Holdings Corp is the larger of the two by market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals.
| ENVX | WGS | |
|---|---|---|
Market Cap | $1.11B | $1.96B |
Sector | Technology | Technology |
52-Week High | $15.93 | $167.51 |
52-Week Low | $4.84 | $34.51 |
Enterprise Value | $1.13B | $1.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $4.855, down 4.05% today amid bearish technical signals. The company shows strong revenue growth potential with recent earnings beats but operates at a significant loss, reflected in a -499.64% net margin. Positive sentiment is driven by analyst consensus with a $12.75 price target and recent operational hires from Apple, though cash flow remains negative as production scales.
Outlook hinges on successful manufacturing ramp-up and smartphone battery qualification. High execution risk and cash burn present challenges, but leadership in silicon-anode technology offers long-term upside if commercial targets are met. Investors face volatility but potential reward from current discounted levels.
GeneDx Holdings Corp. (WGS) trades at $65.785, up 5.37% today, but faces a bearish technical signal with the stock near resistance at $65. The company shows mixed fundamentals with strong revenue growth to $427.54M in 2025 but a net loss of -$21.02M, while analyst consensus remains bullish with a $75.40 price target. Recent news highlights multiple class-action lawsuits alleging securities fraud tied to a 49% stock decline and acquisition underperformance, creating significant investor uncertainty.
The outlook is highly conflicted: strong analyst buy ratings and recent earnings beats contrast with deepening losses, negative cash flow projections for 2026, and legal overhangs. Key risks include litigation outcomes, profitability challenges, and execution missteps, but the stock offers potential upside if the company can stabilize margins and resolve legal issues amid high institutional skepticism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
